North Canton
North Canton
North Canton, Ohio, United States31 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07222566 | |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-10-08 | NCT07033494 | |
| A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-07 | NCT07755410 | |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | anxiety disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 2 | 2026-10-06 | NCT07161700 | |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | anxiety disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07065240 | |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Depressive Disorder, Treatment-Resistant, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-05 | NCT07284667 | |
| A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Active, not recruiting | Phase 3 | 2026-10-05 | NCT06894212 | |
| Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder | Cannabis Withdrawal | Recruiting | Phase 3 | 2026-09-28 | NCT07644052 | |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06564818 | |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT07114874 | |
| NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT07105098 | |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT06480383 | |
| RE104 Safety and Efficacy Study in Generalized Anxiety Disorder | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-24 | NCT07489651 | |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-24 | NCT06951711 | |
| Randomized Study in Children and Adolescents With Migraine: Acute Treatment | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04649242 | |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-22 | NCT06951698 | |
| A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease, thalassemia | Recruiting | Phase 3 | 2026-09-18 | NCT06609226 | |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT06929273 | |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | anxiety disorder, generalized anxiety disorder, psychiatric disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT06809595 | |
| A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, nervous system disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 2 | 2026-09-01 | NCT07459647 | |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-08-31 | NCT06881836 | |
| A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder | Binge-Eating Disorder, Feeding and Eating Disorders, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-08-11 | NCT06878976 | |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-03 | NCT06775379 | |
| Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | Binge-Eating Disorder, Feeding and Eating Disorders, psychiatric disorder | Recruiting | Phase 3 | 2026-07-28 | NCT06413433 | |
| Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-07-27 | NCT07363577 |